Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-BQ7876
- Development stage
- Phase 1
- Lead developer
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-BQ7876 is an investigational radioligand therapy (RLT) developed by the Tomsk National Research Medical Center of the Russian Academy of Sciences for the treatment of prostate cancer. It consists of a urea-based small molecule ligand, BQ7876, which incorporates a DOTA chelator to securely bind the beta-emitting radioisotope lutetium-177 (177Lu). The compound specifically targets prostate-specific membrane antigen (PSMA), a protein highly overexpressed on the surface of metastatic castration-resistant prostate cancer (mCRPC) cells. Upon binding and internalization, the 177Lu isotope delivers localized ionizing radiation, leading to DNA double-strand breaks and subsequent apoptosis of the tumor cells. A Phase 1 clinical trial is currently evaluating its safety, dosimetry, and biodistribution in patients with prostate cancer.
- Other names
- Lutetium-177 labeled BQ7876Lutetium177 labeled BQ7876Lutetium 177 labeled BQ7876177Lu-BQ7876
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on [177Lu]Lu-BQ7876.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-BQ7876.